Arena Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
SAN DIEGO, April 28 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that the company is scheduled to present at the
Morgan Stanley Global Healthcare Unplugged Conference on May 2, 2008 at
9:50 a.m. Eastern Time (6:50 a.m. Pacific Time) at the Ritz-Carlton in Key
Biscayne, Florida. Jack Lief, Arena's President and Chief Executive Officer,
is scheduled to provide an overview of the company, including its clinical
development and discovery programs.
A live audio webcast of the presentation will be available under the
investor relations section of Arena's website at http://www.arenapharm.com. A
replay of the presentation will be available for 30 days following the event.
Please connect to Arena's website several minutes prior to the start of the
webcast to ensure adequate time for any software download that may be
About Arena Pharmaceuticals
Arena is a clinical-stage biopharmaceutical company focused on
discovering, developing and commercializing oral drugs in four major
therapeutic areas: cardiovascular, central nervous system, inflammatory and
metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being
investigated in a Phase 3 clinical trial program for the treatment of obesity.
Arena's broad pipeline of novel compounds targeting G protein-coupled
receptors, an important class of validated drug targets, includes compounds
being evaluated independently and with its partners, Merck & Co., Inc. and
Ortho-McNeil Pharmaceutical, Inc.
Arena Pharmaceuticals® and Arena® are registered service marks of the
company. "APD" is an abbreviation for Arena Pharmaceuticals Development.
Certain statements in this press release are forward-looking statements
that involve a number of risks and uncertainties. Such forward-looking
statements include statements about Arena's strategy, internal and partnered
programs, and ability to develop compounds and commercialize drugs. For such
statements, Arena claims the protection of the Private Securities Litigation
Reform Act of 1995. Actual events or results may differ materially from
Arena's expectations. Factors that could cause actual results to differ
materially from the forward-looking statements include, but are not limited
to, clinical trials and studies may not proceed at the time or in the manner
Arena expects or at all, the results of clinical trials or preclinical studies
may not be predictive of future results, Arena's ability to partner
lorcaserin, APD125, APD791 or other of its compounds or programs, the timing,
success and cost of Arena's research, out-licensing endeavors and clinical
trials, Arena's ability to obtain additional financing, Arena's ability to
obtain and defend its patents, the timing and receipt of payments and fees, if
any, from Arena's collaborators, and Arena's ability to redeem with common
stock any outstanding shares of its series B convertible preferred stock.
Additional factors that could cause actual results to differ materially from
those stated or implied by Arena's forward-looking statements are disclosed in
Arena's filings with the Securities and Exchange Commission. These
forward-looking statements represent Arena's judgment as of the time of this
release. Arena disclaims any intent or obligation to update these
forward-looking statements, other than as may be required under applicable
CONTACT: Jack Lief, President and CEO David Walsey, Director,
Corporate Communications +1-858-453-7200, ext. 1682
Mary Claire Duch Media Relations of WeissComm
Web site: http://www.arenapharm.com
SOURCE Arena Pharmaceuticals, Inc.
You are now leaving arenapharm.com and being directed to a site not maintained by Arena. Arena is not responsible for content or privacy policies on other sites.